Invention Grant
- Patent Title: Oligonucleotides for reduction of PD-L1 expression
-
Application No.: US16664749Application Date: 2019-10-25
-
Publication No.: US10745480B2Publication Date: 2020-08-18
- Inventor: Lykke Pedersen , Hassan Javanbakht , Malene Jackerott , Søren Ottosen , Souphalone Luangsay
- Applicant: Hoffmann-La Roche Inc.
- Applicant Address: US NJ Little Falls
- Assignee: Hoffmann-La Roche, Inc.
- Current Assignee: Hoffmann-La Roche, Inc.
- Current Assignee Address: US NJ Little Falls
- Agency: Holland & Hart LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@1808e929
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C12N15/113 ; A61K38/17 ; A61K39/39 ; A61K39/395 ; A61K45/06 ; A61K39/00

Abstract:
The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
Public/Granted literature
- US20200048344A1 OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION Public/Granted day:2020-02-13
Information query